{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:09:10Z","timestamp":1780657750202,"version":"3.54.1"},"reference-count":25,"publisher":"BMJ","issue":"3","funder":[{"name":"Ministry of Health, Labour and Welfare of Japan"},{"name":"JSPS KAKENHI"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Human T-lymphotropic virus type 1 (HTLV-1) carriers may develop severe systemic diseases, such as adult T cell leukaemia (ATL) or HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP). This study aims to investigate systemic diseases of HTLV-1 carriers who had developed HTLV-1-associated uveitis (HAU).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We investigated the occurrence of systemic diseases in 200 patients with HAU by performing a retrospective investigation of their medical records and examining the results of a postal survey.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean age of HAU onset was 49 years, and the total person-years from HAU onset was 1627. There were two cases of ATL. Of these, one was diagnosed with smouldering ATL at the time of HAU onset and the other developed acute-type ATL 4 years after HAU onset. There were 26 cases of HAM\/TSP; of these, HAM\/TSP occurred first in 13 cases and HAU occurred first in 11 cases. The interval between the onset of HAM\/TSP and HAU ranged from 6 months to 6 years, with no significant difference observed based on whether HAM\/TSP or HAU occurred first. Hyperthyroidism was noted in 45 cases and preceded onset in all cases. HAU onset occurred after starting thiamazole treatment, and in two cases HAU recurred each time thiamazole treatment was restarted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>HTLV-1 carriers with HAU may develop HAM\/TSP more frequently than general carriers. HTLV-1 carriers undergoing treatment for hyperthyroidism may be prone to developing HAU.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2017-310658","type":"journal-article","created":{"date-parts":[[2017,7,9]],"date-time":"2017-07-09T00:20:16Z","timestamp":1499559616000},"page":"373-376","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Systemic diseases in patients with HTLV-1-associated uveitis"],"prefix":"10.1136","volume":"102","author":[{"given":"Kumiko","family":"Nakao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Abematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,7,8]]},"reference":[{"key":"2020050713004506000_102.3.373.1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.77.5.274"},{"key":"2020050713004506000_102.3.373.2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.80.8.719"},{"key":"2020050713004506000_102.3.373.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-5155(99)00099-4"},{"key":"2020050713004506000_102.3.373.4","doi-asserted-by":"publisher","DOI":"10.1016\/0268-960X(88)90012-4"},{"key":"2020050713004506000_102.3.373.5","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.34.713"},{"key":"2020050713004506000_102.3.373.6","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00322"},{"key":"2020050713004506000_102.3.373.7","first-page":"1096","article-title":"The risk of development of HTLV-I-associated myelopathy\/tropical spastic paraparesis among persons infected with HTLV-I","volume":"3","author":"Kaplan","year":"1990","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020050713004506000_102.3.373.8","first-page":"168","article-title":"Clinical features of HTLV-I associated uveitis determined in multicenter collaborative study. Study Group for HTLV-I associated ocular diseases","volume":"38","author":"Ohba","year":"1994","journal-title":"Jpn J Ophthalmol"},{"key":"2020050713004506000_102.3.373.9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1076\/ocii.8.4.235.6454","article-title":"Clinical features of human T-lymphotropic virus type 1 uveitis: a long-term follow-up","volume":"8","author":"Takahashi","year":"2000","journal-title":"Ocul Immunol Inflamm"},{"key":"2020050713004506000_102.3.373.10","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199600001-00020"},{"key":"2020050713004506000_102.3.373.11","doi-asserted-by":"publisher","DOI":"10.1080\/09273940590928670"},{"key":"2020050713004506000_102.3.373.12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2265.1993.tb01006.x","article-title":"Screening for thyroid diseases in an iodine sufficient area with sensitive thyrotrophin assays, and serum thyroid autoantibody and urinary iodide determinations","volume":"38","author":"Konno","year":"1993","journal-title":"Clin Endocrinol"},{"key":"2020050713004506000_102.3.373.13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/BF03401282","article-title":"Hashimoto\u2019s thyroiditis: history and future outlook","volume":"12","author":"Hiromatsu","year":"2013","journal-title":"Hormones"},{"key":"2020050713004506000_102.3.373.14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/jmv.1890380212","article-title":"HTLV-I infection in patients with autoimmune thyroiditis (Hashimoto\u2019s thyroiditis)","volume":"38","author":"Kawai","year":"1992","journal-title":"J Med Virol"},{"key":"2020050713004506000_102.3.373.15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/thy.1994.4.415","article-title":"A high prevalence of human T-lymphotropic virus type I carriers in patients with antithyroid antibodies","volume":"4","author":"Mizokami","year":"1994","journal-title":"Thyroid"},{"key":"2020050713004506000_102.3.373.16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00270582","article-title":"Graves' disease in HTLV-I carriers","volume":"73","author":"Kawai","year":"1995","journal-title":"J Mol Med"},{"key":"2020050713004506000_102.3.373.17","first-page":"153","article-title":"Autoantibodies, human T lymphotropic virus type 1 and type 1 diabetes mellitus in Jamaicans","volume":"51","author":"Smikle","year":"2002","journal-title":"West Indian Med J"},{"key":"2020050713004506000_102.3.373.18","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.78.3.163"},{"key":"2020050713004506000_102.3.373.19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.6.1904"},{"key":"2020050713004506000_102.3.373.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-5710(97)00595-1"},{"key":"2020050713004506000_102.3.373.21","first-page":"332","article-title":"Characteristics of 14 cases of HTLV-1 antibody positive patients who developed uveitis during methimazole treatment","volume":"81","author":"Ohe","year":"2005","journal-title":"Folia Endocrinologica Japonica"},{"key":"2020050713004506000_102.3.373.22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00000441-200208000-00012","article-title":"Severe graves ophthalmopathy accompanied by HTLV-1-associated uveitis (HAU) and anti-neutrophil cytoplasmic antibody-related vasculitis: a case report and a review of the literature of HAU with graves disease","volume":"324","author":"Sarui","year":"2002","journal-title":"Am J Med Sci"},{"key":"2020050713004506000_102.3.373.23","first-page":"258","article-title":"Immunomodulation by methimazole therapy in graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells","volume":"74","author":"Karlsson","year":"1988","journal-title":"Clin Exp Immunol"},{"key":"2020050713004506000_102.3.373.24","first-page":"21","article-title":"Antithyroid drug-induced immunomodulation in graves\u2019 disease patients","volume":"56","author":"Lechpammer","year":"2002","journal-title":"Acta Med Croatica"},{"key":"2020050713004506000_102.3.373.25","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1349-7006.1998.tb03262.x","article-title":"Provirus load in patients with human T-cell leukemia virus type 1 uveitis correlates with precedent graves' disease and disease activities","volume":"89","author":"Ono","year":"1998","journal-title":"Jpn J Cancer Res"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-310658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:55:36Z","timestamp":1601110536000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-310658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,8]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,2,23]]},"published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1136\/bjophthalmol-2017-310658"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310658","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,8]]}}}